Stereotaxis, Inc. STXS
0.86 USD -0.04 (-4.44%)
Nov 12, 2026, 12:33 PM EST
0.8427 Day range 0.90
0.80 52-week range 2.86
- YTD
- -62.61%
- 1 year
- -64.61%
News
benzinga.com TD Cowen Maintains Buy on Stereotaxis, Lowers Price Target to $2 TD Cowen analyst Joshua Jennings maintains Stereotaxis (AMEX:STXS) with a Buy and lowers the price target from $3 to $2.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 13.2% to $1.29 during Wednesday's pre-market session. The company's market cap stands at $5.4 million. The company's, Q2 earnings came…
benzinga.com Why Fossil Group Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket Fossil surged 26% after beating Q3 estimates and raising FY26 sales guidance; SHF and OMH led gainers, while STAK and LWLG fell.
marketbeat.com What Stereotaxis (STXS) Said on Its Q3 Earnings Call Stereotaxis NYSEAMERICAN: STXS reported a 20% increase in third-quarter revenue as early sales of its GenesisX robotic system and Synchrony operating room technology helped offset continuing catheter…
seekingalpha.com Stereotaxis, Inc. (STXS) Q3 2026 Earnings Call Transcript Stereotaxis, Inc. ( STXS ) Q3 2026 Earnings Call November 10, 2026 4:30 PM EST Company Participants David Fischel - CEO & Chairman Kimberly Peery - Chief Financial Officer Conference Call…
benzinga.com Stereotaxis Q3 2026 Earnings Call Transcript Stereotaxis (AMEX:STXS) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 13.9% to $2.2 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Longeveron (NASDAQ:LGVN) stock…
benzinga.com Stereotaxis Announces Up To $24M Convertible Note Financing; $12M Initial Funding Plus $12M Milestone-Based Availability Stereotaxis, Inc. (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with…
benzinga.com Stereotaxis Q3 EPS $(0.07) Misses $(0.05) Estimate, Sales $8.925M Miss $9.600M Estimate Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is unchanged from the same period last year. The…
globenewswire.com Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates ST. LOUIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business…
globenewswire.com Stereotaxis Announces Convertible Note Financing of Up To $24 Million ST. LOUIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…
benzinga.com Stereotaxis Announces 100% Clinical Success Rate For Its Robocath's Robotic System At Transcatheter Cardiovascular Therapeutics Conference; Technical Success Reported At 95% Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the findings from the first-in-human clinical results for…- benzinga.com Canon Medical Systems, Stereotaxis Announce Technology Compatibility And Commercial Collaboration To Pair Alphenix Interventional Imaging Platform With Genesisx Robotic Magnetic Navigation System Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technologyTechnologies will be presented at TCT 2026 in the Canon boothTUSTIN,…
benzinga.com Stereotaxis Says Pauls Stradiņš Clinical University Hospital In Latvia, Establishes Robotic Center For Treatment Of Cardiac Arrhythmias In Latvia And Treats Initial Patients With Genesis Robotic Magnetic Navigation System Pauls Stradiņš Clinical University Hospital installs Genesis Robotic Magnetic Navigation System, establishing the first robotic program for the treatment of cardiac arrhythmia in LatviaFirst…- benzinga.com Citizens Maintains Market Outperform on Stereotaxis, Lowers Price Target to $3 Citizens analyst Daniel Stauder maintains Stereotaxis (AMEX:STXS) with a Market Outperform and lowers the price target from $4 to $3.
- benzinga.com TD Cowen Maintains Buy on Stereotaxis, Lowers Price Target to $3 TD Cowen analyst Joshua Jennings maintains Stereotaxis (AMEX:STXS) with a Buy and lowers the price target from $5 to $3.
benzinga.com Stereotaxis Q2 EPS $(0.05) Beats $(0.06) Estimate, Sales $7.670M Miss $8.350M Estimate Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year. The…
benzinga.com Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partnership with Alabama State University.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased…
- benzinga.com Piper Sandler Reiterates Overweight on Stereotaxis, Lowers Price Target to $3.5 Piper Sandler analyst Adam Maeder reiterates Stereotaxis (AMEX:STXS) with a Overweight and lowers the price target from $4 to $3.5.
benzinga.com Stereotaxis Q1 2026 Earnings Call Transcript - benzinga.com Stereotaxis Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $6.291M Miss $8.620M Estimate Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 14.29 percent increase over losses of $(0.07)…
benzinga.com Earnings Scheduled For May 12, 2026 
benzinga.com Stereotaxis Eyes Billions In Market Opportunity With Robocath Takeover Stereotaxis to acquire Robocath, advancing robotic endovascular tech and accelerating expansion into cardiology and neuro markets.
benzinga.com Stereotaxis To Acquire Robocath, A Venture-Backed Producer Of Robotic Technologies For Interventional Cardiology And Neurointerventions; Terms Not Disclosed This acquisition significantly strengthens Stereotaxis' position as a leading platform for the full spectrum of endovascular procedures, combining complementary technologies to deliver…- benzinga.com Stereotaxis Receives FDA 510(k) Clearance For Synchrony System Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com STX Semiconductor Co. Files Prospectus To Offer Up To $100M In Debt, Equity, Warrants, Rights, And Units $100,000,000 Debt SecuritiesCommon StockPreferred StockWarrantsRightsUnitsWe may offer and sell from time to time, in one or more offerings, up to $100,000,000 in the aggregate of debt securities,…
benzinga.com Stereotaxis Q4 Earnings Summary & Key Takeaways - benzinga.com Stereotaxis Q4 EPS $(0.06), Inline, Sales $8.642M Miss $9.080M Estimate Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.09) per share from the same period…
- benzinga.com Earnings Scheduled For March 9, 2026
benzinga.com Preview: Stereotaxis's Earnings 
benzinga.com This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - benzinga.com Citizens Initiates Coverage On Stereotaxis with Market Outperform Rating, Announces Price Target of $4 Citizens analyst Daniel Stauder initiates coverage on Stereotaxis (AMEX:STXS) with a Market Outperform rating and announces Price Target of $4.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Stereotaxis Q3 EPS $(0.07) Misses $(0.06) Estimate, Sales $7.464M Miss $8.375M Estimate Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 12.5 percent increase over losses of $(0.08)…
benzinga.com Earnings Scheduled For November 11, 2025 
benzinga.com Stereotaxis Granted FDA 510(k) For Its GenesisX RMN System With Navigant Workstation And Cardiodrive As Substantially Equivalent https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K251792- benzinga.com A Look at Stereotaxis's Upcoming Earnings Report
benzinga.com Stereotaxis Receives CE Mark, Seeks FDA Approval for Synchrony Surgical Robotics System Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE Mark in Europe and submitted a 510(k)…
benzinga.com New Robotic System Promises Faster, Safer Care For Arrhythmia Patients Stereotaxis (AMEX: STXS) announces first procedures with Genesis Robotic Magnetic Navigation System for minimally invasive endovascular interventions.- benzinga.com Stereotaxis' Genesis Robotic Magnetic Navigation System Used In First Procedures By Physicians At Erasmus University MC In Netherlands Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced successful first procedures by physicians at Erasmus…
- benzinga.com Stereotaxis Q2 EPS $(0.05) Beats $(0.07) Estimate, Sales $8.798M Beat $7.750M Estimate Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 30.56 percent. This is a 28.57 percent increase over losses of $(0.07)…
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Stereotaxis Receives FDA 510(k) Clearance For MAGiC Sweep Catheter Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration…
- benzinga.com Stereotaxis Announces $12.5M Registered Direct Offering Of Common Stock At $2.00 Per Share Led by Strategic Industry Partner and Select Institutional InvestorsProceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy
- benzinga.com Stereotaxis Q1 EPS $(0.07), Inline, Sales $7.47M Beat $6.88M Estimate Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period…
- benzinga.com Earnings Scheduled For May 12, 2025